BioCryst Pharmaceuticals BCRX Increase (decrease) in contract liabilities and current deferred income
Increase (decrease) in contract liabilities and current deferred income at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income?
- BioCryst Pharmaceuticals (BCRX) reported increase (decrease) in contract liabilities and current deferred income of -$749K in Q1 2026.
- What is the long-term trend for BioCryst Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income?
- Over 3 years (2021 to 2024), BioCryst Pharmaceuticals's increase (decrease) in contract liabilities and current deferred income has grown at a -100.0% compound annual growth rate (CAGR), from $1.28M to $0.
- What does increase (decrease) in contract liabilities and current deferred income mean?
- Represents the net change in deferred revenue or obligations to provide goods or services for which payment has already been received. This metric is a key indicator of future revenue recognition and customer commitment levels.